Symbols / PDSB
PDSB Chart
About
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 37.06M |
| Enterprise Value | 24.06M | Income | -34.88M | Sales | — |
| Book/sh | 0.20 | Cash/sh | 0.54 | Dividend Yield | — |
| Payout | 0.00% | Employees | 24 | IPO | — |
| P/E | — | Forward P/E | -1.01 | PEG | — |
| P/S | — | P/B | 3.42 | P/C | — |
| EV/EBITDA | -0.75 | EV/Sales | — | Quick Ratio | 1.97 |
| Current Ratio | 2.09 | Debt/Eq | 190.06 | LT Debt/Eq | — |
| EPS (ttm) | -0.81 | EPS next Y | -0.67 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 | ROA | -46.22% |
| ROE | -221.81% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 54.72M |
| Shs Float | 45.18M | Short Float | 4.11% | Short Ratio | 2.58 |
| Short Interest | — | 52W High | 2.20 | 52W Low | 0.64 |
| Beta | 1.16 | Avg Volume | 673.46K | Volume | 53.24K |
| Target Price | $9.00 | Recom | Strong_buy | Prev Close | $0.66 |
| Price | $0.68 | Change | 2.75% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.00
Mean price target
2. Current target
$0.68
Latest analyst target
3. DCF / Fair value
$-5.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.68
Low
$3.00
High
$15.00
Mean
$9.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-25 | main | B. Riley Securities | Buy → Buy | $3 |
| 2025-11-13 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-07-01 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-06-11 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-03-27 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2025-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2025-02-24 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-11-25 | main | B. Riley Securities | Buy → Buy | $7 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-10-02 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-09-17 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-08-20 | main | Alliance Global Partners | Buy → Buy | $7 |
| 2024-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-06-12 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-06-12 | main | B. Riley Securities | Buy → Buy | $9 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
- Cancer trial shift seeks faster PDS0101 bid for HPV16 head and neck patients - Stock Titan Fri, 20 Feb 2026 13
- Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail ue, 24 Feb 2026 21
- PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why - Yahoo Finance Mon, 08 Dec 2025 08
- B. Riley Securities Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq ue, 25 Nov 2025 08
- PDS Biotech stock soars after FDA meeting provides accelerated approval path - Investing.com Fri, 09 Jan 2026 08
- PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval - Stocktwits hu, 30 Oct 2025 05
- PDS Biotechnology Corporation Announces $5.3 Million Securities Offering to Support Ongoing Clinical Trials - Quiver Quantitative ue, 11 Nov 2025 08
- Cancer trial tweak could get a new head and neck treatment to patients faster - Stock Titan Fri, 09 Jan 2026 08
- PDS Biotechnology Announces $11.1M Securities Purchase Agreement - TipRanks Wed, 12 Nov 2025 08
- HC Wainwright & Co. Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq hu, 13 Nov 2025 08
- PDS Biotech stock soars after seeking expedited approval pathway for cancer drug - Investing.com Wed, 29 Oct 2025 07
- PDS Biotechnology (NASDAQ: PDSB) notes NK/T-cell gains; 50-patient biomarkers predict response - Stock Titan Mon, 10 Nov 2025 08
- PDS Biotechnology Secures New Patent for PDS0101 - TipRanks ue, 09 Dec 2025 08
- PDS Biotechnology Corporation Seeks Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer Following Promising VERSATILE-002 Trial Results - Quiver Quantitative Wed, 29 Oct 2025 07
- PDS Biotechnology stock falls after $5.3 million registered direct offering - Investing.com ue, 11 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 15060 | 20030 | — | Purchase at price 1.33 per share. | FREITAG GREGORY GENE | Director | — | 2025-02-28 00:00:00 | D |
| 1 | 15061 | 20031 | — | Purchase at price 1.33 per share. | GLOVER STEPHEN C | Director | — | 2025-02-28 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.02 | 0.03 | 0.03 | 0.21 |
| NormalizedEBITDA | -33.79M | -40.12M | -40.74M | -21.43M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -37.61M | -42.94M | -40.85M | -16.92M |
| ReconciledDepreciation | 21.11K | 17.36K | 86.00 | 5.36K |
| EBITDA | -33.79M | -40.12M | -40.74M | -21.43M |
| EBIT | -33.81M | -40.14M | -40.74M | -21.43M |
| NetInterestIncome | -2.16M | -1.30M | -381.34K | 4.35K |
| InterestExpense | 4.67M | 4.21M | 1.32M | 0.00 |
| InterestIncome | 2.51M | 2.90M | 935.18K | 4.35K |
| NormalizedIncome | -37.61M | -42.94M | -40.85M | -16.92M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -37.61M | -42.94M | -40.85M | -16.92M |
| TotalExpenses | 36.32M | 43.05M | 41.67M | 21.44M |
| TotalOperatingIncomeAsReported | -36.32M | -43.05M | -41.67M | -21.44M |
| DilutedAverageShares | 36.45M | 30.95M | 28.60M | 25.60M |
| BasicAverageShares | 36.45M | 30.95M | 28.60M | 25.60M |
| DilutedEPS | -1.03 | -1.39 | -1.43 | -0.66 |
| BasicEPS | -1.03 | -1.39 | -1.43 | -0.66 |
| DilutedNIAvailtoComStockholders | -37.61M | -42.94M | -40.85M | -16.92M |
| NetIncomeCommonStockholders | -37.61M | -42.94M | -40.85M | -16.92M |
| NetIncome | -37.61M | -42.94M | -40.85M | -16.92M |
| NetIncomeIncludingNoncontrollingInterests | -37.61M | -42.94M | -40.85M | -16.92M |
| NetIncomeContinuousOperations | -37.61M | -42.94M | -40.85M | -16.92M |
| TaxProvision | -869.17K | -1.41M | -1.20M | -4.52M |
| PretaxIncome | -38.48M | -44.35M | -42.05M | -21.43M |
| NetNonOperatingInterestIncomeExpense | -2.16M | -1.30M | -381.34K | 4.35K |
| InterestExpenseNonOperating | 4.67M | 4.21M | 1.32M | 0.00 |
| InterestIncomeNonOperating | 2.51M | 2.90M | 935.18K | 4.35K |
| OperatingIncome | -36.32M | -43.05M | -41.67M | -21.44M |
| OperatingExpense | 36.32M | 43.05M | 41.67M | 21.44M |
| ResearchAndDevelopment | 22.57M | 27.76M | 29.43M | 11.25M |
| SellingGeneralAndAdministration | 13.76M | 15.28M | 12.24M | 10.18M |
| GeneralAndAdministrativeExpense | 13.76M | 15.28M | 12.24M | 10.18M |
| OtherGandA | 13.76M | 15.28M | 12.24M | 10.18M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 37.99M | 33.09M | 30.17M | 28.45M |
| ShareIssued | 37.99M | 33.09M | 30.17M | 28.45M |
| TotalDebt | 21.83M | 23.85M | 23.47M | 490.35K |
| TangibleBookValue | 19.00M | 26.13M | 44.00M | 63.21M |
| InvestedCapital | 40.71M | 49.80M | 67.02M | 63.21M |
| WorkingCapital | 27.97M | 45.43M | 66.66M | 63.08M |
| NetTangibleAssets | 19.00M | 26.13M | 44.00M | 63.21M |
| CapitalLeaseObligations | 122.97K | 178.77K | 452.05K | 490.35K |
| CommonStockEquity | 19.00M | 26.13M | 44.00M | 63.21M |
| TotalCapitalization | 28.21M | 45.64M | 67.02M | 63.21M |
| TotalEquityGrossMinorityInterest | 19.00M | 26.13M | 44.00M | 63.21M |
| StockholdersEquity | 19.00M | 26.13M | 44.00M | 63.21M |
| RetainedEarnings | -182.11M | -144.50M | -101.56M | -60.70M |
| AdditionalPaidInCapital | 201.10M | 170.62M | 145.55M | 123.90M |
| CapitalStock | 12.54K | 10.92K | 9.96K | 9.39K |
| CommonStock | 12.54K | 10.92K | 9.96K | 9.39K |
| TotalLiabilitiesNetMinorityInterest | 26.35M | 33.26M | 33.01M | 3.99M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 9.27M | 19.63M | 23.18M | 231.43K |
| LongTermDebtAndCapitalLeaseObligation | 9.27M | 19.63M | 23.18M | 231.43K |
| LongTermCapitalLeaseObligation | 61.85K | 122.97K | 164.01K | 231.43K |
| LongTermDebt | 9.20M | 19.51M | 23.02M | |
| CurrentLiabilities | 17.09M | 13.63M | 9.82M | 3.76M |
| CurrentDebtAndCapitalLeaseObligation | 12.56M | 4.22M | 288.04K | 258.92K |
| CurrentCapitalLeaseObligation | 61.12K | 55.79K | 288.04K | 258.92K |
| CurrentDebt | 12.50M | 4.17M | ||
| OtherCurrentBorrowings | 12.50M | 4.17M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 663.40K | 1.29M | 1.84M | 1.46M |
| PayablesAndAccruedExpenses | 3.86M | 8.12M | 7.70M | 2.04M |
| CurrentAccruedExpenses | 2.18M | 1.14M | 6.48M | 729.39K |
| InterestPayable | 252.32K | 306.77K | 280.38K | 0.00 |
| Payables | 1.68M | 6.98M | 1.22M | 1.31M |
| AccountsPayable | 1.68M | 6.98M | 1.22M | 1.31M |
| TotalAssets | 45.36M | 59.39M | 77.01M | 67.20M |
| TotalNonCurrentAssets | 304.21K | 335.00K | 527.53K | 357.70K |
| NetPPE | 304.21K | 335.00K | 527.53K | 357.70K |
| AccumulatedDepreciation | -153.89K | -132.78K | -115.42K | -115.33K |
| GrossPPE | 458.11K | 467.78K | 642.95K | 473.03K |
| OtherProperties | 429.60K | 439.27K | 461.80K | 86.91K |
| MachineryFurnitureEquipment | 28.51K | 28.51K | 28.51K | 28.51K |
| BuildingsAndImprovements | 0.00 | 152.65K | 357.61K | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 45.05M | 59.06M | 76.48M | 66.84M |
| OtherCurrentAssets | 3.36M | 2.49M | 2.66M | 1.60M |
| PrepaidAssets | 1.60M | |||
| CashCashEquivalentsAndShortTermInvestments | 41.69M | 56.56M | 73.82M | 65.24M |
| CashAndCashEquivalents | 41.69M | 56.56M | 73.82M | 65.24M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -35.06M | -33.64M | -25.71M | -12.49M |
| RepaymentOfDebt | -3.18M | -59.30K | 0.00 | |
| IssuanceOfDebt | 0.00 | 25.00M | 0.00 | |
| IssuanceOfCapitalStock | 22.60M | 16.13M | 9.86M | 48.54M |
| CapitalExpenditure | -29.00K | |||
| InterestPaidSupplementalData | 3.56M | 3.54M | 852.22K | 0.00 |
| EndCashPosition | 41.69M | 56.56M | 73.82M | 65.24M |
| BeginningCashPosition | 56.56M | 73.82M | 65.24M | 28.84M |
| ChangesInCash | -14.87M | -17.26M | 8.58M | 36.40M |
| FinancingCashFlow | 20.19M | 16.38M | 34.29M | 48.89M |
| CashFlowFromContinuingFinancingActivities | 20.19M | 16.38M | 34.29M | 48.89M |
| NetOtherFinancingCharges | -720.29K | |||
| ProceedsFromStockOptionExercised | 774.09K | 308.94K | 151.42K | 344.12K |
| NetCommonStockIssuance | 22.60M | 16.13M | 9.86M | 48.54M |
| CommonStockIssuance | 22.60M | 16.13M | 9.86M | 48.54M |
| NetIssuancePaymentsOfDebt | -3.18M | -59.30K | 25.00M | 0.00 |
| NetLongTermDebtIssuance | -3.18M | -59.30K | 25.00M | 0.00 |
| LongTermDebtPayments | -3.18M | -59.30K | 0.00 | |
| LongTermDebtIssuance | 0.00 | 25.00M | 0.00 | |
| InvestingCashFlow | -29.00K | 0.00 | ||
| CashFlowFromContinuingInvestingActivities | -29.00K | 0.00 | ||
| NetPPEPurchaseAndSale | -29.00K | 0.00 | ||
| PurchaseOfPPE | -29.00K | 0.00 | ||
| OperatingCashFlow | -35.03M | -33.64M | -25.71M | -12.49M |
| CashFlowFromContinuingOperatingActivities | -35.03M | -33.64M | -25.71M | -12.49M |
| ChangeInWorkingCapital | -5.75M | -199.28K | 4.47M | 75.82K |
| ChangeInOtherCurrentLiabilities | 0.00 | -239.47K | -74.36K | -170.84K |
| ChangeInOtherCurrentAssets | 0.00 | -423.88K | 0.00 | |
| ChangeInPayablesAndAccruedExpense | -4.88M | -125.48K | 6.04M | 346.56K |
| ChangeInAccruedExpense | 416.52K | -5.89M | 6.13M | 452.38K |
| ChangeInPayable | -5.30M | 5.76M | -90.12K | -105.82K |
| ChangeInAccountPayable | -5.30M | 5.76M | -90.12K | -105.82K |
| ChangeInPrepaidAssets | -870.29K | 165.67K | -1.06M | -99.90K |
| OtherNonCashItems | 1.46M | 1.87M | 5.47M | 241.03K |
| StockBasedCompensation | 6.85M | 7.61M | 5.20M | 4.11M |
| DepreciationAmortizationDepletion | 21.11K | 17.36K | 86.00 | 5.36K |
| DepreciationAndAmortization | 21.11K | 17.36K | 86.00 | 5.36K |
| Depreciation | 21.11K | 17.36K | 86.00 | 5.36K |
| NetIncomeFromContinuingOperations | -37.61M | -42.94M | -40.85M | -16.92M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PDSB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|